美国药品安全治理模式初探

中国药物评价 ›› 2020, Vol. 37 ›› Issue (1): 71-75.

美国药品安全治理模式初探

杜婧,陈永法

中国药科大学国际医药商学院

收稿日期:2019-12-03 修回日期:2020-01-23 出版日期:2020-02-28 发布日期:2020-03-30
基金资助:
国家社会科学基金

A Preliminary Study on the Drug Governance in the United States

Received:2019-12-03 Revised:2020-01-23 Online:2020-02-28 Published:2020-03-30
Contact: Fa YongChen E-mail:cyf990@163.com
Supported by:
食品药品安全协同治理的国际比较研究

摘要/Abstract

摘要： Objective：This paper explores the evolution path of the US drug safety governance， and then summarizes the current governance status.Finally， provide relevantsuggestionsin three aspects：perfect drug safety information sharing， optimize public-private cooperation， and promote public participationin the progress of decision-making.

关键词: 美国药品安全治理, 公私合作, 公众参与

Abstract: Objective：This paper explores the evolution path of the US drug safety governance， and then summarizes the current governance status.Finally， provide relevantsuggestionsin three aspects：perfect drug safety information sharing， optimize public-private cooperation， and promote public participationin the progress of decision-making.

Key words: US drug safety governance, Public-private partnership, Public participation

中图分类号:

R954

杜婧陈永法. 美国药品安全治理模式初探[J]. 中国药物评价, 2020, 37(1): 71-75.

参考文献

[1]格里·斯托克，华夏风.作为理论的治理：五个论点[J].国际社会科学杂志(中文版)，1999，1：19-30.
[2]胡庆亮.推进国家治理体系现代化的逻辑与理路：从党政二元一体到主体多元共治[J].求实，2015，9：12-17.
[3]Medication Guides — Adding a Toll-Free Number for Reporting Adverse Events[EB/OL] [2009-06].https：//www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm164669.
[4]Consumer Representatives on FDA Advisory Committees[EB/OL].https：//www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/CommitteeMembership/ucm231782.htm.
[5]Transparency and Open Government[EB/OL].（2009-01-21）. https：//www.govinfo.gov/content/pkg/FR-2009-01-26/pdf/E9-1777.
[6]沙勇忠，赵润娣.美国开放政府计划背景下的公众参与——进展、问题及启示[J]. 南京社会科学， 2015，11：77-83.
[7]Allan R J.PPP： a review of literature and practice [C].Saskatchewan Institute of Public Policy Paper， 4.1999
[8]杨莉，田丽娟，罗刚.美国药品安全监管机制研究及启示[J].中国药房, 2017, 28(4):437-441
[9]曹立亚.美国药品安全监管历程与监测体系[M]. 北京：中国医药科技出版社， 2006.
[10]Prescription Drug User Fee Act (PDUFA)：2017 Reauthorization as PDUFA VI[EB/OL].（2017-06-08） [2018-03-16]. https：//www.everycrsreport.com/reports/R44864.html#_Toc508972893.
[11]邱宣.美国政府决策的机构咨询与公众咨询[J]. 特区实践与理论， 2009，3：41-44.
[12]Advisory Committee Laws， Regulations and Guidance[EB/OL].https：//www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/LawsRegulationsGuidance/default.htm.
[13]吴海红.欧洲、美国与中国药品注册收费管理制度的分析比较与思考[D].浙江工业大学，2019.
[14]两部门确定药品医疗器械注册收费标准[EB/OL].[2015-06-02]. http：//finance.stockstar.com/SS2015060200000937.shtml.
[15]中华人民共和国药品管理法（修订草案）征求意见[EB/OL].[2019-04-28]. http：//www.law-lib.com/fzdt/newshtml/20/20190428092604.htm.
[16]陈永法，覃红艺.我国公众参与食品和药品安全治理的不足及对策[J].中国药房, 2016, 27(16):2164-2167